| pubmed-article:19182832 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:19182832 | lifeskim:mentions | umls-concept:C0008059 | lld:lifeskim |
| pubmed-article:19182832 | lifeskim:mentions | umls-concept:C1504389 | lld:lifeskim |
| pubmed-article:19182832 | lifeskim:mentions | umls-concept:C0006463 | lld:lifeskim |
| pubmed-article:19182832 | lifeskim:mentions | umls-concept:C0009647 | lld:lifeskim |
| pubmed-article:19182832 | lifeskim:mentions | umls-concept:C1979963 | lld:lifeskim |
| pubmed-article:19182832 | lifeskim:mentions | umls-concept:C2003903 | lld:lifeskim |
| pubmed-article:19182832 | lifeskim:mentions | umls-concept:C0201734 | lld:lifeskim |
| pubmed-article:19182832 | lifeskim:mentions | umls-concept:C2348070 | lld:lifeskim |
| pubmed-article:19182832 | lifeskim:mentions | umls-concept:C0205171 | lld:lifeskim |
| pubmed-article:19182832 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:19182832 | pubmed:dateCreated | 2009-8-12 | lld:pubmed |
| pubmed-article:19182832 | pubmed:abstractText | We studied the pharmacokinetic (PK) profile of single daily dose i.v. BU in children who underwent reduced-intensity conditioning (RIC) transplantation. A cohort of 19 patients < or =4 years of age (group 1) and 33 patients >4 years (group 2) was studied. Patients received a BU test dose for PK studies, followed by two treatment doses adjusted to target an area under the curve (AUC) of 4000 microM min per day. Patients in group 1 attained a lower AUC as compared to group 2 (3568 vs 4035 microM min). In group 1, 67% patients and in group 2, 84% patients achieved AUC within the targeted range. Stable donor chimerism was achieved in 56% patients in group 1 and 79% in group 2. Eight patients required a second transplantation because of graft failure. Because of the concern that a low AUC adversely affected outcomes, a second cohort of 23 patients followed a modified protocol with a targeted AUC of 5000 microM min. A higher AUC was attained (4825 microM min). Stable donor chimerism was achieved in 91% of patients. Our results show that RIC regimens using two single daily doses of i.v. BU are effective in children, but a targeted AUC of 5000 microM min is recommended. | lld:pubmed |
| pubmed-article:19182832 | pubmed:language | eng | lld:pubmed |
| pubmed-article:19182832 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19182832 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:19182832 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19182832 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19182832 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:19182832 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:19182832 | pubmed:issn | 1476-5365 | lld:pubmed |
| pubmed-article:19182832 | pubmed:author | pubmed-author:ChaudhurySS | lld:pubmed |
| pubmed-article:19182832 | pubmed:author | pubmed-author:SchneidermanJ... | lld:pubmed |
| pubmed-article:19182832 | pubmed:author | pubmed-author:JacobsohnDD | lld:pubmed |
| pubmed-article:19182832 | pubmed:author | pubmed-author:HayJ CJC | lld:pubmed |
| pubmed-article:19182832 | pubmed:author | pubmed-author:KletzelMM | lld:pubmed |
| pubmed-article:19182832 | pubmed:author | pubmed-author:DuerstRR | lld:pubmed |
| pubmed-article:19182832 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:19182832 | pubmed:volume | 44 | lld:pubmed |
| pubmed-article:19182832 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:19182832 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:19182832 | pubmed:pagination | 145-56 | lld:pubmed |
| pubmed-article:19182832 | pubmed:meshHeading | pubmed-meshheading:19182832... | lld:pubmed |
| pubmed-article:19182832 | pubmed:meshHeading | pubmed-meshheading:19182832... | lld:pubmed |
| pubmed-article:19182832 | pubmed:meshHeading | pubmed-meshheading:19182832... | lld:pubmed |
| pubmed-article:19182832 | pubmed:meshHeading | pubmed-meshheading:19182832... | lld:pubmed |
| pubmed-article:19182832 | pubmed:meshHeading | pubmed-meshheading:19182832... | lld:pubmed |
| pubmed-article:19182832 | pubmed:meshHeading | pubmed-meshheading:19182832... | lld:pubmed |
| pubmed-article:19182832 | pubmed:meshHeading | pubmed-meshheading:19182832... | lld:pubmed |
| pubmed-article:19182832 | pubmed:meshHeading | pubmed-meshheading:19182832... | lld:pubmed |
| pubmed-article:19182832 | pubmed:meshHeading | pubmed-meshheading:19182832... | lld:pubmed |
| pubmed-article:19182832 | pubmed:meshHeading | pubmed-meshheading:19182832... | lld:pubmed |
| pubmed-article:19182832 | pubmed:meshHeading | pubmed-meshheading:19182832... | lld:pubmed |
| pubmed-article:19182832 | pubmed:meshHeading | pubmed-meshheading:19182832... | lld:pubmed |
| pubmed-article:19182832 | pubmed:meshHeading | pubmed-meshheading:19182832... | lld:pubmed |
| pubmed-article:19182832 | pubmed:meshHeading | pubmed-meshheading:19182832... | lld:pubmed |
| pubmed-article:19182832 | pubmed:meshHeading | pubmed-meshheading:19182832... | lld:pubmed |
| pubmed-article:19182832 | pubmed:meshHeading | pubmed-meshheading:19182832... | lld:pubmed |
| pubmed-article:19182832 | pubmed:year | 2009 | lld:pubmed |
| pubmed-article:19182832 | pubmed:articleTitle | Age-dependent pharmacokinetic profile of single daily dose i.v. busulfan in children undergoing reduced-intensity conditioning stem cell transplant. | lld:pubmed |
| pubmed-article:19182832 | pubmed:affiliation | Department of Pediatrics, Children's Memorial Hospital, Northwestern University, Chicago, IL 60614, USA. | lld:pubmed |
| pubmed-article:19182832 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:19182832 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
